Clinical Trials Logo

Myelofibrosis; Anemia clinical trials

View clinical trials related to Myelofibrosis; Anemia.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03208803 Completed - Clinical trials for Myelofibrosis; Anemia

Combination of JAK2 Inhibitor and Erythropoiesis-stimulating Agent in Myelofibrosis

Ruxo-EPO
Start date: May 2016
Phase:
Study type: Observational

In patients with myelofibrosis, ruxolitinib is a current therapeutic option, which has demonstrated rapid and durable reduction in splenomegaly and improved disease-related symptoms. Anemia is another frequent issue in myelofibrosis. Consistent with its JAK2 signalling inhibition, ruxolitinib therapy has been shown to be detrimental on the hemoglobin level, increasing the depth of anemia or transfusion need. Despite potential antagonistic mechanisms of action on Janus Kinase 2, some responses on anemia have been reported with the addition of Erythropoiesis-stimulating Agent to ruxolitinib in a small subset of patients in the COMFORT II study. Ruxo-EPO is an observational study aimed to better assess the combination of Erythropoiesis-stimulating Agent and a Janus Kinase 2 inhibitor for therapeutic efficacy on anemia, Myelofibrosis evolution and for tolerance, in a larger cohort of patients treated for myelofibrosis in general practice.